Skip to main content

Advertisement

SpringerLink
Log in

Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations

  • Special Issue
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Psychopharmacotherapy should now be regulated in the sense of evidence-based medicine, as is the case in other areas of clinical treatment in medicine. In general this is a meaningful development, which principally will have a positive impact on routine health care in psychiatry. But several related problems should not be ignored. So far consensus on an internationally accepted evidence graduation could not be reached due to several difficulties related to this. For example, focussing on the results of meta-analyses instead of considering relevant single studies results in a decision-making logic which is in conflict with the rationale applied by drug authorities in the licensing process. Another example is the relevance of placebo-controlled trials: if randomized placebo-controlled phase-III studies are prioritized in the evidence grading, the evidence possibly deviates too far from the conditions of routine clinical care due to the special selection of patients in those studies. However, a grading primarily based on active comparator trials could lead to wrong conclusions about efficacy. This concerns especially the so-called “effectiveness” studies and other forms of phase-IV studies with their less restrictive methodological rigidity. Attempts to regulate psychopharmacotherapy in the sense of evidence-based medicine come closer to their limits the more complex the clinical situation and the respective decision-making logic are. Even in times of evidence-based medicine a large part of complex clinical decision-making in psychopharmacotherapy still relies more on clinical experience and a consensus on clinical experience, traditions and belief systems than on results of efficacy oriented phase-III and effectiveness-oriented phase-IV clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adli M, Rush J, Möller HJ, Bauer M (2003) Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 36 (Suppl 3):S222–S229

    PubMed  Google Scholar 

  2. Adli M, Bauer M, Rush AJ (2006) Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 59:1029–1038

    Article  PubMed  Google Scholar 

  3. Altman DG, Andersen PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492–1495

    CAS  PubMed  Google Scholar 

  4. American Association of Clinical Endocrinologists, American Diabetes Association, American Psychiatric Association, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601

    Article  Google Scholar 

  5. American Psychiatric Association APA Guideline Development Process (2006) http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm

  6. Antes G (2004) The evidence base of clinical practice guidelines, health technology assessments and patient information as a basis for clinical decision-making. Z Ärztl Fortbild Qualitätssich 98:180–184

    PubMed  Google Scholar 

  7. Ascher-Svanum H, Zhu B, Faries D, Ernst FR (2004) A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 3:11

    Article  PubMed  Google Scholar 

  8. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J (2006) Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8

    Article  PubMed  CAS  Google Scholar 

  9. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D et al (2004) Grading quality of evidence and strength of recommendations. BMJ 19:1490

    Google Scholar 

  10. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O’Connell D, Oxman AD, Phillips B et al (2004) Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 4:38

    Article  PubMed  Google Scholar 

  11. Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N et al (2005) Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 5:25

    Article  PubMed  Google Scholar 

  12. Baghai TC, Möller HJ, Rupprecht R (2006) Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des 12:503–515

    Article  CAS  PubMed  Google Scholar 

  13. Baldwin DS (2006) Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes? CNS Spectr 11:34–39

    PubMed  Google Scholar 

  14. Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22–28

    Article  PubMed  Google Scholar 

  15. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety (2003) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3:171–199

    Google Scholar 

  16. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety (2008) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312

    Google Scholar 

  17. Bateman A, Fonagy P (1999) Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 156:1563–1569

    CAS  PubMed  Google Scholar 

  18. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43

    Google Scholar 

  19. Bauer M, Whybrow PC, Angst J (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3:69–86

    Article  PubMed  Google Scholar 

  20. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Unipolar Depressive Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8:67–104

    Google Scholar 

  21. Bauer M, Tharmanathan P, Volz HP, Möller HJ, Freemantle N (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259:172–185

    Article  PubMed  Google Scholar 

  22. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR (2009) Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 23:574–591

    Google Scholar 

  23. Bottlender R, Rudolf D, Strauss A, Moller HJ (1998) Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. Eur Psychiatry 248:296–300

    CAS  Google Scholar 

  24. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, Tyrer P (2000) Framework for design and evaluation of complex interventions to improve health. BMJ 321:694–696

    Article  CAS  PubMed  Google Scholar 

  25. Carpenter WT (2001) Evidence-based treatment for first-episode schizophrenia? Am J Psychiatry 158:1771–1773

    Article  PubMed  Google Scholar 

  26. Cartabellotta A, Minella C, Bevilacqua L, Caltagirone P (1998) Evidence-based medicine. 3. Systematic reviews: a tool for clinical practice, permanent education and health policy decisions. Italian Group on Evidence-Based Medicine-GIMBE. Recenti Prog Med 89:329–337

    CAS  PubMed  Google Scholar 

  27. Cartabellotta A, Montalto G, Notarbartolo A (1998) Evidence-based medicine. How to use biomedical literature to solve clinical problems. Italian Group on Evidence-Based Medicine-GIMBE. Minerva Med 89:105–115

    CAS  PubMed  Google Scholar 

  28. Catty J, Burns T, Comas A (2001) Day centres for severe mental illness. Cochrane Database Syst Rev: CD001710

  29. Chilvers R, Macdonald GM, Hayes AA (2002) Supported housing for people with severe mental disorders. Cochrane Database Syst Rev: CD000453

  30. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758

    Article  CAS  PubMed  Google Scholar 

  31. Citrome L (2007) Show me the evidence: using number needed to treat. South Med J 100:881–884

    PubMed  Google Scholar 

  32. Clark W, Mucklow J (1998) Gathering and weighing the evidence. In: Panton R, Chapman S (eds) Medicines Management. BMJ Books and Pharmaceutical Press, London, pp 59–74

  33. Committee for Proprietary Medicinal Products (CPMP) (2002) Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.eu.int

  34. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic Combinations vs Monotherapy in Schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35:443–457

    Article  PubMed  Google Scholar 

  35. Craig JC, Irwig LM, Stockler MR (2001) Evidence-based medicine:useful tools for decision making. MJA 174:248–253

    CAS  PubMed  Google Scholar 

  36. Crowther R, Marshall M, Bond G, Huxley P (2003) Vocational rehabilitation for people with severe mental illness (Cochrane Review) [computer program]. In: The Cochrane library, issue 3. Update Software, Oxford

  37. Cuffel B, Martin J, Joyce AT, Boccuzzi SJ, Loebel A (2006) Lipid and glucose monitoring during atypical antipsychotic treatment: effects of the 2004 ADA/APA consensus statement. Poster presented at the 2006 APA Annual Meeting, Toronto, Canada, 20–25 May 2006

  38. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553–564

    Article  CAS  PubMed  Google Scholar 

  39. Delaney B (2006) Is society losing control of the medical research agenda? BMJ 332:1063–1064

    Article  PubMed  Google Scholar 

  40. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J et al (2004) Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65:312–321

    CAS  PubMed  Google Scholar 

  41. Eccles M, Mason J (2001) How to develop cost-conscious guidelines. Health Technol Assess 5(16):1–69

    CAS  PubMed  Google Scholar 

  42. Eccles M, Grimshaw J, Campbell M, Ramsay C (2003) Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care 12:47–52

    Article  CAS  PubMed  Google Scholar 

  43. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA (2006) Effectiveness of switching antipsychotic medications. Am J Psychiatry 163:2090–2095

    Article  PubMed  Google Scholar 

  44. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132–191

    Google Scholar 

  45. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5–40

    Article  PubMed  Google Scholar 

  46. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF et al (2003) Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457–494

    Article  PubMed  Google Scholar 

  47. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172

    Article  PubMed  Google Scholar 

  48. Feinstein AR (1995) Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48:71–79

    Article  CAS  PubMed  Google Scholar 

  49. Fritze J, Möller HJ (2001) Design of clinical trials of antidepressants. Should a placebo control arm be included? CNS Drugs 15:755–764

    Article  CAS  PubMed  Google Scholar 

  50. Fulford KWM (2004) Facts/values: ten principles of value-based medicine. In: Radden J (ed) The philosophy of psychiatry: a companion. New York, Oxford University Press, pp 205–236

    Google Scholar 

  51. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS (2005) Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 187:248–255

    Article  PubMed  Google Scholar 

  52. Geddes J, Freemantle N, Harrison P, Bebbington P, for the National Schizophrenia Guideline Development Group (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376

    Google Scholar 

  53. Geddes JR, Freemantle N, Mason J, Eccles M, Boynton J (2000) SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev: CD001851

  54. Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9

    Article  PubMed  Google Scholar 

  55. Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L (1999) Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. Harv Rev Psychiatry 7:1–28

    Article  CAS  PubMed  Google Scholar 

  56. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537–1547

    Article  PubMed  Google Scholar 

  57. Gonzalez DD (2001) From evidence-based medicine to medicine-based evidence. An Esp Pediatr 55:429–439

    Google Scholar 

  58. Gorouhi F, Jafarian S, Firooz A (2007) Reporting of number needed to treat and its difficulties. J Am Acad Dermatol 57:729–730

    Article  PubMed  Google Scholar 

  59. Gray SH (2002) Evidence-based psychotherapeutics. J Am Acad Psychoanal 30:3–16

    Article  PubMed  Google Scholar 

  60. Gray GE, Pinson LA (2003) Evidence-based medicine and psychiatric practice. Psychiatr Q 74:387–399

    Article  PubMed  Google Scholar 

  61. Greenhalgh T (2006) How to read a paper: the basics of evidence based medicine, 3rd edn. BMJ Books/Blackwell, London

    Google Scholar 

  62. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L et al (2004) Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 8:iii–iv, 1–72

    Google Scholar 

  63. Grimshaw J, Eccles M, Thomas R, MacLennan G, Ramsay C, Fraser C, Vale L (2006) Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966–1998. J Gen Intern Med 21(Suppl 2):S14–S20

    PubMed  Google Scholar 

  64. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2002) World Federation of Societies of Biological Psychiary (WFSBP) guidelines for biological treatment of bipolar disorders, Part I: treatment of bipolar depression. World J Biol Psychiatry 3:115–124

    Article  PubMed  Google Scholar 

  65. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ (2003) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part II: treatment of mania. World J Biol Psychiatry 4:5–13

    Article  PubMed  Google Scholar 

  66. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ (2004) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part III: maintenance treatment. World J Biol Psychiatry 5:120–135

    Article  PubMed  Google Scholar 

  67. Grunze H, Vieta E, Guy M, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S, WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 10:85–116

    Article  PubMed  Google Scholar 

  68. Gupta M (2007) Does evidence-based medicine apply to psychiatry? Theor Med Bioeth 28:103–120

    Article  PubMed  Google Scholar 

  69. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:174–181

    Article  PubMed  Google Scholar 

  70. Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schunemann H (2006) An emerging consensus on grading recommendations? ACP J Club 144:A8–A9

    PubMed  Google Scholar 

  71. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926

    Article  PubMed  Google Scholar 

  72. Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008) Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59:1121–1130

    Article  PubMed  Google Scholar 

  73. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ et al (2003) The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 107:222–232

    Article  CAS  PubMed  Google Scholar 

  74. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D et al (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17:235–244

    Article  CAS  PubMed  Google Scholar 

  75. Hegerl U, Plattner A, Moller HJ (2004) Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 254:99–107

    Article  PubMed  Google Scholar 

  76. Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I et al (2009) Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439–449

    Article  CAS  PubMed  Google Scholar 

  77. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185–194

    Article  PubMed  Google Scholar 

  78. Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J et al (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826–837

    CAS  PubMed  Google Scholar 

  79. Holsboer F (2008) How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 8:638–646

    Article  CAS  Google Scholar 

  80. Jadad AR, Phil D, Cook DJ (1998) Methodology and reports of systematic reviews and meta-analyses-acomparison of Cochrane reviews with articles published in paper-based journals. JAMA 280:278–280

    Article  CAS  PubMed  Google Scholar 

  81. Jiang Q, Ahmed S (2009) An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder. Ann Gen Psychiatry 8:4

    Article  PubMed  Google Scholar 

  82. Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, Mavrogiorgou P, Hegerl U (2007) Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry 68:1206–1212

    Article  PubMed  Google Scholar 

  83. Kallert TW (2005) [Is mental health services research in need of randomised controlled trials?] Braucht psychiatrische Versorgungsforschung randomisierte kontrollierte Studien? Psychiatr Prax 32:375–377

    Article  PubMed  Google Scholar 

  84. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24:62–67

    CAS  PubMed  Google Scholar 

  85. Kane JM, Honigfeld G, Singer J, Meltzer HY (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 48:789–796

    Google Scholar 

  86. Kawamura T, Tamakoshi A, Wakai K, Ohno Y (1999) Evidence-based medicine and ‘The Cochrane Collaboration’. Nippon Koshu Eisei Zasshi 46:498–506

    CAS  PubMed  Google Scholar 

  87. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:260–268

    Article  Google Scholar 

  88. Kjaergard LL, Is-Nielsen B (2002) Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 325:249

    Article  PubMed  Google Scholar 

  89. Klein DF (2000) Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 157:1204–1211

    Article  CAS  PubMed  Google Scholar 

  90. Kunz R, Vist G, Oxman A (2007) Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 18(2):MR000012

    Google Scholar 

  91. Lehman AF, Steinwachs DM (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24:1–10

    CAS  PubMed  Google Scholar 

  92. Leichsenring F, Rabung S, Leibing E (2004) The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 61:1208–1216

    Article  PubMed  Google Scholar 

  93. Lerer B, Macciardi F (2002) Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 5:255–275

    Article  CAS  PubMed  Google Scholar 

  94. Leucht S (2004) Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 7:S15–S20

    Article  CAS  PubMed  Google Scholar 

  95. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589

    Article  CAS  PubMed  Google Scholar 

  96. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447

    Article  CAS  PubMed  Google Scholar 

  97. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41

    Article  CAS  PubMed  Google Scholar 

  98. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Lobos CA, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163

    Article  PubMed  Google Scholar 

  99. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB (2005) Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30:445–460

    Article  CAS  PubMed  Google Scholar 

  100. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  CAS  PubMed  Google Scholar 

  101. Linden M (2005) Leitlinien und die Psychologie medizinischer Entscheidungsprozesse bei der Behandlung depressiver Erkrankungen [Guidelines and the psychology of medical decision making in the treatment of depressive disorders]. Fortschr Neurol Psychiat 73:249–258

    Article  CAS  PubMed  Google Scholar 

  102. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N (2006) Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 63:757–766

    Article  PubMed  Google Scholar 

  103. Lohr KN (2004) Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 16:9–18

    Article  PubMed  Google Scholar 

  104. Maier W, Möller HJ (2005) Metaanalyses—highest level of empirical evidence? Eur Arch Psychiatry Clin Neurosci 255:369–370

    Article  PubMed  Google Scholar 

  105. Maier W, Möller HJ (2008) Meta-analyses: a method to maximize the evidence from clinical studies? Eur Arch Psychiatry Clin Neurosci (in preparation)

  106. Manser R, Walters EH (2001) What is evidence-based medicine and the role of the systematic review: the revolution coming your way. Monaldi Arch Chest Dis 56:33–38

    CAS  PubMed  Google Scholar 

  107. Marshall M, Lockwood A (2003) Assertive communication treatment for people with severe mental disorder (Cochrane Review) [computer program]. In: The Cochrane library, issue 3. Update Software, Oxford

  108. Marshall M, Gray A, Lockwood A, Green R (2003) Case management for people with severe mental disorders (Cochrane Review) [computer program]. Update Software, Oxford

  109. Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D (2003) Day hospital versus admission for acute psychiatric disorders. Cochrane Database Syst Rev: CD004026

  110. McCabe C, Dixon S (2000) Testing the validity of cost-effectiveness models. Pharmacoeconomics 17:501–513

    Article  CAS  PubMed  Google Scholar 

  111. McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26:733–744

    Article  PubMed  Google Scholar 

  112. Melander H, Ahlqvist-rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173

    Article  PubMed  Google Scholar 

  113. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008) A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627

    Article  CAS  PubMed  Google Scholar 

  114. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354:1896–1900

    Article  CAS  PubMed  Google Scholar 

  115. Möller HJ (2000) State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 1:204–214

    Article  PubMed  Google Scholar 

  116. Möller HJ (2006) Ethical aspects of publishing. World J Biol Psychiatry 7:66–69

    Article  PubMed  Google Scholar 

  117. Möller HJ (2008) Do effectiveness (“real world”) studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 258:257–270

    Article  PubMed  Google Scholar 

  118. Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455

    Article  PubMed  Google Scholar 

  119. Möller HJ (2009) Declaration of conflicts of interest in scientific publications. World J Biol Psychiatry 10:2–5 Editorial

    Article  PubMed  Google Scholar 

  120. Möller HJ (2009) Standardised rating scales in Psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 10:6–26

    Article  PubMed  Google Scholar 

  121. Möller HJ, Grunze H (2000) Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 250:57–68

    Article  PubMed  Google Scholar 

  122. Möller HJ, Grunze H, Broich K (2006) Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 256:1–16

    Article  PubMed  Google Scholar 

  123. Möller HJ, Langer S, Schmauss M (2007) Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry 40:53–57

    Article  PubMed  CAS  Google Scholar 

  124. Möller HJ, Baldwin D, Goodwin G, Kasper S, Okasha A, Stein DJ, Tandon R, Versiani M (2008) Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 258:3–23

    Article  PubMed  Google Scholar 

  125. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME (2008) Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 63:424–434

    Article  CAS  PubMed  Google Scholar 

  126. NICE National Institute for Health and Clinical Excellence Anxiety (amended): Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. (2007) CG22

  127. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530

    Article  PubMed  Google Scholar 

  128. O’Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D et al (2005) Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 23:529–536

    Article  PubMed  Google Scholar 

  129. Ollenschlager G, Berenbeck C, Low A, Stobrawa F, Kolkmann FW (2002) The National Program for disease management—guidelines under the auspices of the German Medical Association—a method report. Z Arztl Fortbild Qualitatssich 96:545–548

    PubMed  Google Scholar 

  130. Patsopoulos NA, Ioannidis JP, Analatos AA (2006) Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ 332:1061–1064

    Article  PubMed  Google Scholar 

  131. Pilling S, Price K (2006) Developing and implementing clinical guidelines: lessons from the NICE schizophrenia guideline. Epidemiol Psichiatr Soc 15:109–116

    PubMed  Google Scholar 

  132. REJr Kelly, Cohen LJ, Semple RJ, Bialer P, Lau A, Bodenheimer A et al (2006) Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 36:1647–1656

    Article  Google Scholar 

  133. Riedel M, Strassnig N, Müller N, Zwack P, Möller HJ (2005) How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255:143–148

    Article  CAS  PubMed  Google Scholar 

  134. Rush AJ (2007) STAR*D: What have we learned? Am J Psychiatry 164:201–204

    Article  PubMed  Google Scholar 

  135. Rush JA, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K et al (2003) Texas Medication Algorithm Project, Phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 64:357–369

    Article  PubMed  Google Scholar 

  136. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM et al (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142

    Article  PubMed  Google Scholar 

  137. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917

    Article  PubMed  Google Scholar 

  138. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF et al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242

    Article  CAS  PubMed  Google Scholar 

  139. Sackett DL (2000) Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone, New York

  140. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312:71–72

    CAS  PubMed  Google Scholar 

  141. Sheehan DV, Burnham DB, Iyengar MK, Perera P, for the Paxil CR Panic Disorder Study Group (2005) Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 66:34–40

    Google Scholar 

  142. Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ (2008) Differences in medication adherence and healthcare resource utilization patterns. older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22:963–973

    Article  PubMed  Google Scholar 

  143. Stauffer V, Karagianis J, Sutton V, Ascher-Svanum H, Treuer T, Silva de Lima M, Ball T, Poole-Hoffmann V, Tohen M (2008) Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in randomized, blinded trials comparing olanzapine to other atypical antipsychotics for treatment of schizophrenia. Clin Schizophr Relat Psychoses: 136–146

  144. Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53:1119–1129

    Article  CAS  PubMed  Google Scholar 

  145. Stone JM, Davis JM, Leucht S, Pilowsky LS (2009) Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs—an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 35:789–797

    Article  PubMed  Google Scholar 

  146. Stroup TC (2007) Heterogeneity of treatment effects in schizophrenia. Am J Med 120:526–531

    Article  CAS  Google Scholar 

  147. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK, For the CATIE Investigators (2009) Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107: 1–12

    Google Scholar 

  148. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (2008) What CATIE found: results from the schizophrenia trial. Psychiatr Serv 59:500–506

    Article  PubMed  Google Scholar 

  149. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Möller HJ et al (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20–38

    Article  PubMed  Google Scholar 

  150. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B et al (2004) Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61:669–680

    Article  PubMed  Google Scholar 

  151. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM et al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252

    Article  CAS  PubMed  Google Scholar 

  152. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40

    Article  PubMed  Google Scholar 

  153. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publications of antidepressant trials and its influence on apparent efficacy. N Eng J Med 358:252–260

    Article  CAS  Google Scholar 

  154. Wampold BE, Minami T, Baskin TW, Callen TS (2002) A meta-(re)analysis of the effects of cognitive therapy versus ‘other therapies’ for depression. J Affect Disord 68:159–165

    Article  PubMed  Google Scholar 

  155. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR (2007) The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 9:449–459

    Article  PubMed  Google Scholar 

  156. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA (2006) Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 188:410–415

    Article  PubMed  Google Scholar 

  157. Yank V, Rennie D, Bero LA (2007) Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335:1202–1205

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstrasse 7, 80336, Munich, Germany

    Hans-Jürgen Möller

  2. Department of Psychiatry, University of Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany

    Wolfgang Maier

Authors
  1. Hans-Jürgen Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Jürgen Möller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möller, HJ., Maier, W. Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci 260, 25–39 (2010). https://doi.org/10.1007/s00406-009-0070-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-009-0070-9

Keywords

Search

Navigation